tradingkey.logo

Ipsen: Elafibranor Shows Favorable Safety Profile And Efficacy In PSC

ReutersApr 24, 2025 6:16 AM

- Ipsen SA IPN.PA:

  • ELAFIBRANOR SHOWS FAVORABLE SAFETY PROFILE AND EFFICACY IN PSC

  • A SIGNIFICANT IMPROVEMENT IN PRURITUS WAS OBSERVED IN PATIENTS ON ELAFIBRANOR 120 MG VERSUS PLACEBO

  • ELAFIBRANOR IMPROVES LIVER BIOCHEMICAL PARAMETERS IN PSC PATIENTS

  • PHASE II ELMWOOD TRIAL SHOWS POSITIVE SAFETY AND EFFICACY FOR ELAFIBRANOR

  • ELAFIBRANOR STABILIZES NON-INVASIVE MARKERS OF LIVER FIBROSIS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI